Presented by: University of Kentucky Department of Pathology

“On A Scale of One to Ten, You are an XI”

Aaron D Shmookler, MD

Medical Director: Coagulation Laboratory

University of Kentucky

Department of Pathology and Laboratory Medicine

          Thursday, September 17, 2026

12:00 – 1:00pm

In-Person MS 147 or Zoom: https://us06web.zoom.us/j/88974250308

Passcode: 710932

 Use the QR code to register for this Grand Rounds if you have not already registered.

At the completion of this lecture attendees should be able to:

1. Differentiate laboratory and clinical (in vivo) models of coagulation (#Cascade #SorryNotSorry)
2. Describe clinical thrombosis and hemostasis
3. Explain the evolutionary and historical context for coagulation factor XI (FXI)
4. Evaluate the rational for targeting FXI/FXIa as a promising target for anticoagulation
5. Summarize the efficacy and safety of anti-FXI/FXIa [anti-FXI(a)] clinical trials

6. Disclosure of Financial Interest Summary to Learners

    

   All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

    

   None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.

    

   The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

   Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation